Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

ATA 200

Drug Profile

ATA 200

Alternative Names: ATA-200; GNT-0007; LGMD-R5/LGMD2C gene therapy - Atamyo Therapeutics

Latest Information Update: 01 Apr 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Atamyo Therapeutics
  • Class Gene therapies
  • Mechanism of Action Gene transference; Sarcoglycan replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Limb girdle muscular dystrophies
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Limb girdle muscular dystrophies

Most Recent Events

  • 26 Mar 2024 Italian Medicines Agency (AIFA) and French Medicines Agency (ANSM) approves a Clinical Trial Application (CTA) authorization for ATA 200 in Limb girdle muscular dystrophies in Italy and France respectively
  • 19 Sep 2023 Atamyo Therapeutics plans a phase Ib/II trial for Limb girdle muscular dystrophies (In children) in France and Italy (IV), in May 2024 (NCT05973630) (EudraCT-2023-506440-16-00)
  • 19 Sep 2023 Atmyo Therapeutics files a Clinical Trials application with the European Commission in Europe for Limb-girdle muscular dystrophy
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top